Transient T cell depletion causes regression of melanoma metastases

Cancer Statistics, 2005

2005 • 5,487 citations

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1996 • 2,073 citations

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

1999 • 1,967 citations

Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity

1999 • 1,475 citations

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

1999 • 1,066 citations

Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses

2001 • 1,033 citations

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

2005 • 998 citations

Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

2005 • 878 citations

Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells

2004 • 680 citations

Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells

2004 • 541 citations

Tregs and rethinking cancer immunotherapy

2007 • 532 citations

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

2006 • 437 citations

Homeostatic proliferation is a barrier to transplantation tolerance

2003 • 403 citations

T cell homeostatic proliferation elicits effective antitumor autoimmunity

2002 • 312 citations

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

1998 • 298 citations

Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma

2005 • 293 citations

Cutaneous melanoma

2005 • 281 citations

T cell homeostatic proliferation elicits effective antitumor autoimmunity

2002 • 262 citations

Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells

2004 • 251 citations

Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential

2005 • 239 citations

Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice.

2002 • 214 citations

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

1998 • 206 citations

Development of antitumor immune responses in reconstituted lymphopenic hosts.

2002 • 136 citations

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.

2000 • 82 citations

Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia

2006 • 48 citations

CD25+ regulatory T cells and tumor immunity

2003 • 30 citations